United Kingdom

Catabasis Pharmaceuticals Q2 loss per share $0.32

Thursday, 10 Aug 2017 

Aug 10 (Reuters) - Catabasis Pharmaceuticals Inc :Catabasis Pharmaceuticals reports second quarter 2017 financial results and reviews business progress.Q2 loss per share $0.32.Q2 earnings per share view $-0.40 -- Thomson Reuters I/B/E/S.Catabasis Pharmaceuticals Inc - ‍continue to advance open-label extension and expect to share 24-week edasalonexent results in Q3.Catabasis Pharmaceuticals Inc - ‍phase 3 clinical trial plan for edasalonexent in second half of 2017​.Catabasis Pharmaceuticals Inc - ‍as of June 30, cash and cash equivalents of $29.4 million, versus $31.8 million last quarter.Catabasis Pharmaceuticals Inc - ‍Catabasis expects that its current operating plan provides for cash to fund operations through August, 2018​. 

Company Quote

-0.0403 -5.84%
12 Nov 2018